Vyne Therapeutics Inc (VYNE)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David Domzalski
Employees:
30
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NJ, 08807
800-775-7936
Date | Ratio |
---|---|
2021-02-16 | 1:4 |
2023-02-13 | 1:18 |
VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|